Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals

Clicks: 254
ID: 266457
2018
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
An important subgroup of people who inject drugs (PWID) receiving opioid agonist therapy (OAT) cannot be treated in the setting of a hepatology centre and would not regularly ingest their medication when handed to them for self-administration. Our hypothesis was that chronic hepatitis C in these pat …
Reference Key
a2018journaldirectly Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Schütz A;Moser S;Schwanke C;Schubert R;Luhn J;Gutic E;Lang T;Schleicher M;Haltmayer H;Gschwantler M;;
Journal journal of viral hepatitis
Year 2018
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/29316001
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult 80 and over Genotype substance abuse hepacivirus / isolation & purification intravenous / complications* chronic / drug therapy* antiviral agents / administration & dosage* hepacivirus / classification hepacivirus / genetics sustained virologic response Medication Adherence pmid:29316001 doi:10.1111/jvh.12857 a schütz s moser m gschwantler benzimidazoles / administration & dosage* directly observed therapy* fluorenes / administration & dosage* sofosbuvir / administration & dosage*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.